Search details
1.
Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas.
Blood
; 142(22): 1871-1878, 2023 11 30.
Article
in English
| MEDLINE | ID: mdl-37494698
2.
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia.
Br J Haematol
; 204(5): 1825-1829, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38286472
3.
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma.
Anticancer Drugs
; 35(1): 63-69, 2024 01 01.
Article
in English
| MEDLINE | ID: mdl-37067996
4.
Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Cancer
; 129(14): 2179-2191, 2023 07 15.
Article
in English
| MEDLINE | ID: mdl-37021929
5.
Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia.
Br J Haematol
; 196(4): 963-968, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34697797
6.
Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia.
Br J Haematol
; 199(2): 239-244, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35841338
7.
Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results.
Hematol Oncol
; 40(4): 695-703, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-35488778
8.
Efficacy of proteasome inhibitor-based maintenance following autologous transplantation in multiple myeloma: A systematic review and meta-analysis.
Eur J Haematol
; 106(1): 40-48, 2021 Jan.
Article
in English
| MEDLINE | ID: mdl-32799387
9.
Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis.
Br J Haematol
; 191(5): 673-681, 2020 12.
Article
in English
| MEDLINE | ID: mdl-32298469
10.
Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature.
J Natl Compr Canc Netw
; 18(5): 517-521, 2020 05.
Article
in English
| MEDLINE | ID: mdl-32380464
11.
In-Hospital Mortality and Post-Transplantation Complications in Elderly Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Population-Based Study.
Biol Blood Marrow Transplant
; 23(7): 1203-1207, 2017 Jul.
Article
in English
| MEDLINE | ID: mdl-28286198
12.
Ixazomib and lenalidomide maintenance therapy in multiple myeloma.
Ann Hematol
; 100(3): 851-853, 2021 Mar.
Article
in English
| MEDLINE | ID: mdl-33161454
13.
Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives.
Front Oncol
; 14: 1394048, 2024.
Article
in English
| MEDLINE | ID: mdl-38660139
14.
Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities.
Blood Cancer J
; 14(1): 86, 2024 May 28.
Article
in English
| MEDLINE | ID: mdl-38806475
15.
Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia.
J Clin Oncol
; : JCO2302066, 2024 May 24.
Article
in English
| MEDLINE | ID: mdl-38788183
16.
IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies.
Front Immunol
; 14: 1239082, 2023.
Article
in English
| MEDLINE | ID: mdl-37954584
17.
Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety.
Curr Oncol
; 30(11): 9627-9633, 2023 Oct 31.
Article
in English
| MEDLINE | ID: mdl-37999117
18.
Chimeric Antigen Receptor T-cell Therapy for Chronic Lymphocytic Leukemia: What is the supporting evidence so far?
Clin Hematol Int
; 5(4): 33-46, 2023.
Article
in English
| MEDLINE | ID: mdl-38817957
19.
Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myeloma: a single center experience.
Bone Marrow Transplant
; 58(10): 1130-1136, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37479753
20.
The digital divide: Racial disparities in adoption and utilization of health information technology among patients with lymphoid cancers.
Cancer Med
; 12(18): 19013-19020, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37587868